In today’s rapidly evolving digital landscape, leadership in software quality assurance is crucial to the success of any technology-driven organization. Sonali Sheetal stands as a formidable force in ...

The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...

CI gains 14.7% YTD as Evernorth and Cigna Healthcare drive growth, but rising expenses and debt pose challenges.

Officials held a ribbon-cutting on Wednesday for Kelley’s Field II, a new independent living community in Hinesburg.

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE:CI) with a price target of $390. Rice shared his views ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...